Drug intelligence / Profile preview

axitinib + pembrolizumab-activated autologous DC-CIK cells

Development stage: Unknown
Lead developer: Sun Yat-sen University
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Oral, Intravenous

Overview

This combination therapy, developed by Sun Yat-sen University Cancer Center, is an investigational regimen for advanced or metastatic renal cell carcinoma (mRCC). It consists of axitinib, a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR-1, -2, and -3) to inhibit tumor angiogenesis, and autologous dendritic cell-cytokine induced killer (DC-CIK) cells. These DC-CIK cells are prepared from the patient's own peripheral blood and are activated ex vivo with the anti-PD-1 monoclonal antibody pembrolizumab before being re-infused. The combination aims to synergize the anti-angiogenic effects of axitinib with the enhanced anti-tumor immune response provided by the activated cellular immunotherapy. A Phase II trial (NCT02886897) has evaluated this regimen, showing promising clinical activity in patients with metastatic RCC.

Other names: Pembrolizumab-activated D-CIK and AxitinibD-CIK + pembrolizumab + axitinib

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)

Beyond the preview

Go deeper on axitinib + pembrolizumab-activated autologous DC-CIK cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on axitinib + pembrolizumab-activated autologous DC-CIK cells.

Explore the full profile